Cassava Sciences: Downside From Alzheimer’s Results Possible Despite Developments (SAVA)

1 min read
101 views

This article was written by

Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don’t constitute investment advice.

Analyst’s Disclosure: I/we have a beneficial short position in the shares of SAVA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Read the full article here

Leave a Reply

Your email address will not be published.

Previous Story

AeroVironment Could Surge From Agentic AI (NASDAQ:AVAV)

Next Story

Sow Good Inc. (SOWG) Q4 2024 Earnings Call Transcript

Latest from News